Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Peripheral Nervous System: Ganglia and Nerves01:24

Peripheral Nervous System: Ganglia and Nerves

The Peripheral Nervous System (PNS) is a crucial component of the body's neural network, extending beyond the central nervous system (CNS) to bridge the gap between the CNS and the external environment. It encompasses nerves, ganglia, and sensory receptors.
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis.

JNCI cancer spectrum·2026
Same author

Focused ultrasound for brain metastases.

Neuro-oncology advances·2026
Same author

Applications of transcranial focused ultrasound for primary brain tumors.

Neuro-oncology advances·2026
Same author

Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study.

Scientific reports·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Association between radiographic response and subsequent recurrence in brain metastases treated with radiation: implications for response assessment criteria.

Neuro-oncology·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Primary central nervous system lymphoma.

Manmeet S Ahluwalia1, David M Peereboom

  • 1Brain Tumor and Neuro-Oncology Center/Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH, 44195, USA.

Current Treatment Options in Neurology
|September 16, 2010
PubMed
Summary
This summary is machine-generated.

High-dose methotrexate (MTX) is the cornerstone for newly diagnosed primary central nervous system lymphoma (PCNSL). Radiation therapy is reserved for relapse, and clinical trials are crucial for advancing PCNSL treatment.

More Related Videos

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain
08:03

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain

Published on: March 10, 2026

Related Experiment Videos

Last Updated: Jun 8, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain
08:03

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain

Published on: March 10, 2026

Area of Science:

  • Neuro-oncology
  • Hematology
  • Pharmacology

Background:

  • Primary central nervous system lymphoma (PCNSL) management aims for long-term disease control, neurological complication management, and neurocognitive function preservation.
  • Chemotherapy, particularly high-dose methotrexate (MTX), is the established cornerstone for newly diagnosed PCNSL.
  • Radiation therapy, especially whole-brain radiation, carries significant risks of long-term neurocognitive toxicity.

Purpose of the Study:

  • To outline current management strategies for primary central nervous system lymphoma (PCNSL).
  • To emphasize the role of high-dose methotrexate (MTX) in newly diagnosed PCNSL.
  • To discuss the appropriate use of radiation therapy and alternative chemotherapy delivery methods.

Main Methods:

  • Review of current treatment paradigms for PCNSL.
  • Emphasis on high-dose intravenous methotrexate (MTX) regimens (>3 g/m(2)) for newly diagnosed disease.
  • Discussion of radiation therapy's role, reserved primarily for relapse or specific presentations.
  • Consideration of alternative chemotherapy delivery methods like autologous stem cell rescue and intra-arterial chemotherapy within clinical trials.
  • Management strategies for ocular involvement and leptomeningeal disease (LMD) are detailed.

Main Results:

  • High-dose intravenous MTX is recommended as the cornerstone for newly diagnosed PCNSL, either as monotherapy or in combination regimens.
  • Radiation therapy is generally reserved for disease relapse, with lower-dose or fractionated approaches explored in clinical trials to mitigate neurocognitive toxicity.
  • Specific strategies are required for ocular lymphoma and leptomeningeal involvement, including intravitreal chemotherapy and intrathecal MTX.
  • Entry into clinical trials is strongly encouraged due to the rarity of PCNSL and the need for treatment advancement.

Conclusions:

  • High-dose methotrexate-based chemotherapy is the primary treatment for newly diagnosed PCNSL.
  • Radiation therapy should be used judiciously, primarily for relapse, to minimize long-term neurocognitive deficits.
  • Individualized treatment approaches are necessary for specific PCNSL presentations, such as ocular or leptomeningeal disease.
  • Clinical trial participation is essential for improving outcomes in this rare malignancy.